1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline Insights, 2014

SUMMARY
DelveInsight’s,“ Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Cognitive Impairment Associated With Schizophrenia (CIAS). This report provides information on the therapeutic development based on the Cognitive Impairment Associated With Schizophrenia (CIAS) dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS)
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Cognitive Impairment Associated With Schizophrenia (CIAS) and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Cognitive Impairment Associated With Schizophrenia (CIAS)
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline Insights, 2014
Table of Contents
- Cognitive Impairment Associated With Schizophrenia (CIAS) Overview
- Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Therapeutics
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics under Development by Companies
- Cognitive Impairment Associated With Schizophrenia (CIAS) Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Cognitive Impairment Associated With Schizophrenia (CIAS) Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Cognitive Impairment Associated With Schizophrenia (CIAS) Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Cognitive Impairment Associated With Schizophrenia (CIAS) Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products
- Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Products
- Companies Involved in Therapeutics Development for Cognitive Impairment Associated With Schizophrenia (CIAS)
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Cognitive Impairment Associated With Schizophrenia (CIAS) Assessment by Monotherapy Products
- Cognitive Impairment Associated With Schizophrenia (CIAS) Assessment by Combination Products
- Cognitive Impairment Associated With Schizophrenia (CIAS) Assessment by Route of Administration
- Cognitive Impairment Associated With Schizophrenia (CIAS) Assessment by Stage and Route of Administration
- Cognitive Impairment Associated With Schizophrenia (CIAS) Assessment by Molecule Type
- Cognitive Impairment Associated With Schizophrenia (CIAS) Assessment by Stage and Molecule Type
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics - Discontinued Products
- Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Cognitive Impairment Associated With Schizophrenia (CIAS) Assessment by Monotherapy Products
- Cognitive Impairment Associated With Schizophrenia (CIAS) Assessment by Combination Products
- Cognitive Impairment Associated With Schizophrenia (CIAS) Assessment by Route of Administration
- Cognitive Impairment Associated With Schizophrenia (CIAS) Assessment by Stage and Route of Administration
- Cognitive Impairment Associated With Schizophrenia (CIAS) Assessment by Molecule Type
- Cognitive Impairment Associated With Schizophrenia (CIAS) Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Alcoholism and drug dependence and addiction, known as substance use disorders and rehabilitation treatments are classified as substance abuse treatment. Some of the common symptoms of drug abuse are ...

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Psychotherapeutic drugs are used to treat mental illnesses such as extreme mood swings, social withdrawal, long lasting depression, confused thinking, and suicidal thought. schizophrenia, bipolar disorder, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.